The effects of (-)-epicatechin on endothelial cells involve the G protein-coupled estrogen receptor (GPER)

Pharmacological Research

Volumn 100, Issue , 2015, Pages 309-320

  Moreno Ulloa, Aldo ^a,b   Mendez Luna, David ^b   Beltran Partida, Ernesto ^c   Castillo, Carmen ^b   Guevara, Gustavo ^b   Ramirez Sanchez, Israel ^a,b   Correa Basurto, José ^b   Ceballos, Guillermo ^b   Villarreal, Francisco ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE BAJA CALIFORNIA   (Mexico)

Author keywords

( ) Epicatechin; Cacao; Docking; EGFR; ERK 1 2; GPER

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CYCLIC AMP; EPICATECHIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; F ACTIN; G PROTEIN COUPLED ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ACTIN; CATECHIN; CELL SURFACE RECEPTOR; ESTROGEN; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PHENYLEPHRINE;

ACTIN FILAMENT; ANIMAL CELL; ARTICLE; CELL SURFACE; CONTROLLED STUDY; CORONARY ARTERY; ENDOTHELIUM CELL; ENZYME ACTIVATION; EX VIVO STUDY; INTRACELLULAR SIGNALING; MALE; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; VASODILATATION; ANIMAL; ARTERY; BOVINE; CELL CULTURE; DRUG EFFECTS; METABOLISM; SIGNAL TRANSDUCTION; WISTAR RAT;

ACTINS; ANIMALS; ARTERIES; CATECHIN; CATTLE; CELLS, CULTURED; ENDOTHELIAL CELLS; ESTROGENS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MALE; NITRIC OXIDE; PHENYLEPHRINE; RATS; RATS, WISTAR; RECEPTORS, CELL SURFACE; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; VASODILATION;

EID: 84941128004     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.08.014     Document Type: Article

References (62)

1. A. Buitrago-Lopez, J. Sanderson, L. Johnson, S. Warnakula, A. Wood, E. Di Angelantonio, and O.H. Franco Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis BMJ 343 2011 d4488
2. E. Mostofsky, E.B. Levitan, A. Wolk, and M.A. Mittleman Chocolate intake and incidence of heart failure: a population-based prospective study of middle-aged and elderly women Circ. Heart Fail. 3 5 2010 612 616
3. B. Buijsse, E.J. Feskens, F.J. Kok, and D. Kromhout Cocoa intake, blood pressure, and cardiovascular mortality: the Zutphen Elderly Study Arch. Intern. Med. 166 4 2006 411 417
4. B. Buijsse, C. Weikert, D. Drogan, M. Bergmann, and H. Boeing Chocolate consumption in relation to blood pressure and risk of cardiovascular disease in German adults Eur. Heart J. 31 13 2010 1616 1623
5. S. Ellinger, A. Reusch, P. Stehle, and H.P. Helfrich Epicatechin ingested via cocoa products reduces blood pressure in humans: a nonlinear regression model with a Bayesian approach Am. J. Clin. Nutr. 95 6 2012 1365 1377
6. W.M. Loke, J.M. Hodgson, J.M. Proudfoot, A.J. McKinley, I.B. Puddey, and K.D. Croft Pure dietary flavonoids quercetin and (-)-epicatechin augment nitric oxide products and reduce endothelin-1 acutely in healthy men Am. J. Clin. Nutr. 88 4 2008 1018 1025
7. H. Schroeter, C. Heiss, J. Balzer, P. Kleinbongard, C.L. Keen, N.K. Hollenberg, H. Sies, C. Kwik-Uribe, H.H. Schmitz, and M. Kelm (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans Proc. Natl. Acad. Sci. U. S. A. 103 4 2006 1024 1029
8. I. Ramirez-Sanchez, L. Maya, G. Ceballos, and F. Villarreal (-)-Epicatechin activation of endothelial cell endothelial nitric oxide synthase, nitric oxide, and related signaling pathways Hypertension 55 6 2010 1398 1405
9. B.D. Manning, and L.C. Cantley AKT/PKB signaling: navigating downstream Cell 129 7 2007 1261 1274
10. T.B. Patel Single transmembrane spanning heterotrimeric g protein-coupled receptors and their signaling cascades Pharmacol. Rev. 56 3 2004 371 385
11. A. Moreno-Ulloa, D. Romero-Perez, F. Villarreal, G. Ceballos, and I. Ramirez-Sanchez Cell membrane mediated (-)-epicatechin effects on upstream endothelial cell signaling: evidence for a surface receptor Bioorg. Med. Chem. Lett. 24 12 2014 2749 2752
12. G.G. Kuiper, J.G. Lemmen, B. Carlsson, J.C. Corton, S.H. Safe, P.T. van der Saag, B. van der Burg, and J.A. Gustafsson Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta Endocrinology 139 10 1998 4252 4263
13. T.T. Wang, N. Sathyamoorthy, and J.M. Phang Molecular effects of genistein on estrogen receptor mediated pathways Carcinogenesis 17 2 1996 271 275
14. V. Breinholt, and J.C. Larsen Detection of weak estrogenic flavonoids using a recombinant yeast strain and a modified MCF7 cell proliferation assay Chem. Res. Toxicol. 11 6 1998 622 629
15. P. Thomas, Y. Pang, E.J. Filardo, and J. Dong Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells Endocrinology 146 2 2005 624 632
16. C.G. Bologa, C.M. Revankar, S.M. Young, B.S. Edwards, J.B. Arterburn, A.S. Kiselyov, M.A. Parker, S.E. Tkachenko, N.P. Savchuck, L.A. Sklar, T.I. Oprea, and E.R. Prossnitz Virtual and biomolecular screening converge on a selective agonist for GPR30 Nat. Chem. Biol. 2 4 2006 207 212
17. E.J. Filardo, J.A. Quinn, K.I. Bland, and A.R. Frackelton Jr Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF Mol. Endocrinol. 14 10 2000 1649 1660
18. M.R. Meyer, N.C. Fredette, T.A. Howard, C. Hu, C. Ramesh, C. Daniel, K. Amann, J.B. Arterburn, M. Barton, and E.R. Prossnitz G protein-coupled estrogen receptor protects from atherosclerosis Sci. Rep. 4 2014 7564
19. D.J. Rowlands, S. Chapple, R.C. Siow, and G.E. Mann Equol-stimulated mitochondrial reactive oxygen species activate endothelial nitric oxide synthase and redox signaling in endothelial cells: roles for F-actin and GPR30 Hypertension 57 4 2011 833 840
20. E.R. Prossnitz, and M. Barton Estrogen biology: new insights into GPER function and clinical opportunities Mol. Cell. Endocrinol. 389 1-2 2014 71 83
21. D. Mendez-Luna, M. Martinez-Archundia, R.C. Maroun, G. Ceballos-Reyes, M.J. Fragoso-Vazquez, D.E. Gonzalez-Juarez, and J. Correa-Basurto Deciphering the GPER/GPR 30-agonist and antagonists interactions using molecular modeling studies, molecular dynamics, and docking simulations J. Biomol. Struct. Dyn. 33 10 2015 2161 2172
22. J. Zhang, and Y. Zhang GPCRRD: G protein-coupled receptor spatial restraint database for 3D structure modeling and function annotation Bioinformatics 26 23 2010 3004 3005
23. R. Lappano, M.F. Santolla, M. Pupo, M.S. Sinicropi, A. Caruso, C. Rosano, and M. Maggiolini MIBE acts as antagonist ligand of both estrogen receptor alpha and GPER in breast cancer cells Breast Cancer Res. 14 1 2012 R12
24. A. Moreno-Ulloa, A. Cid, I. Rubio-Gayosso, G. Ceballos, F. Villarreal, and I. Ramirez-Sanchez Effects of (-)-epicatechin and derivatives on nitric oxide mediated induction of mitochondrial proteins Bioorg. Med. Chem. Lett. 23 15 2013 4441 4446
25. L. Dana, J.S. Felice, and Rui Hai Liu A modified methylene blue assay for accurate cell counting J. Funct. Foods 1 1 2009 109 118
26. C. Castillo-Hernandez Mdel, N. Meraz-Cruz, G. Guevara-Balcazar, J. Lopez-Canales, O. Lopez-Canales, N. Galindo, and C. Castillo-Henkel Age-related differences in the beta-adrenergic vasodilator response in rat aortic rings Proc. West. Pharmacol. Soc. 53 2010 29 32
27. S.B. Cheng, J.A. Quinn, C.T. Graeber, and E.J. Filardo Down-modulation of the G-protein-coupled estrogen receptor, GPER, from the cell surface occurs via a trans-Golgi-proteasome pathway J. Biol. Chem. 286 25 2011 22441 22455
28. R. Gros, Q. Ding, B. Liu, J. Chorazyczewski, and R.D. Feldman Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation Am. J. Physiol. Cell Physiol. 304 6 2013 C532 C540
29. M.K. Dennis, A.S. Field, R. Burai, C. Ramesh, W.K. Petrie, C.G. Bologa, T.I. Oprea, Y. Yamaguchi, S. Hayashi, L.A. Sklar, H.J. Hathaway, J.B. Arterburn, and E.R. Prossnitz Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity J. Steroid Biochem. Mol. Biol. 127 3-5 2011 358 366
30. M.K. Dennis, R. Burai, C. Ramesh, W.K. Petrie, S.N. Alcon, T.K. Nayak, C.G. Bologa, A. Leitao, E. Brailoiu, E. Deliu, N.J. Dun, L.A. Sklar, H.J. Hathaway, J.B. Arterburn, T.I. Oprea, and E.R. Prossnitz In vivo effects of a GPR30 antagonist Nat. Chem. Biol. 5 6 2009 421 427
31. A. Levitzki, and A. Gazit Tyrosine kinase inhibition: an approach to drug development Science 267 5205 1995 1782 1788
32. J.H. Hanke, J.P. Gardner, R.L. Dow, P.S. Changelian, W.H. Brissette, E.J. Weringer, B.A. Pollok, and P.A. Connelly Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation J. Biol. Chem. 271 2 1996 695 701
33. G.J. Della Rocca, S. Maudsley, Y. Daaka, R.J. Lefkowitz, and L.M. Luttrell Pleiotropic coupling of G protein-coupled receptors to the mitogen-activated protein kinase cascade. Role of focal adhesions and receptor tyrosine kinases J. Biol. Chem. 274 20 1999 13978 13984
34. Q. Ding, R. Gros, L.E. Limbird, J. Chorazyczewski, and R.D. Feldman Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR 30 Am. J. Physiol. Cell Physiol. 297 5 2009 C1178 C1187
35. S.H. Lindsey, L. Liu, and M.C. Chappell Vasodilation by GPER in mesenteric arteries involves both endothelial nitric oxide and smooth muscle cAMP signaling Steroids 81 2014 99 102
36. X. Yu, F. Li, E. Klussmann, J.N. Stallone, and G. Han G protein-coupled estrogen receptor 1 mediates relaxation of coronary arteries via cAMP/PKA-dependent activation of MLCP Am. J. Physiol. Endocrinol. Metab. 307 4 2014 E398 E407
37. E.J. Filardo, J.A. Quinn, A.R. Frackelton Jr., and K.I. Bland Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis Mol. Endocrinol. 16 1 2002 70 84
38. P.A. Insel, and R.S. Ostrom Forskolin as a tool for examining adenylyl cyclase expression, regulation, and G protein signaling Cell. Mol. Neurobiol. 23 3 2003 305 314
39. S.H. Lindsey, K.A. Carver, E.R. Prossnitz, and M.C. Chappell Vasodilation in response to the GPR30 agonist G-1 is not different from estradiol in the mRen2. Lewis female rat J. Cardiovasc. Pharmacol. 57 5 2011 598 603
40. S. Arefin, T. Simoncini, R. Wieland, F. Hammarqvist, S. Spina, L. Goglia, and K. Kublickiene Vasodilatory effects of the selective GPER agonist G-1 is maximal in arteries of postmenopausal women Maturitas 78 2 2014 123 130
41. Z.L. Li, J.C. Liu, S.B. Liu, X.Q. Li, D.H. Yi, and M.G. Zhao Improvement of vascular function by acute and chronic treatment with the GPR30 agonist G1 in experimental diabetes mellitus PLoS One 7 6 2012 e38787
42. D.Y. Oh, S. Talukdar, E.J. Bae, T. Imamura, H. Morinaga, W. Fan, P. Li, W.J. Lu, S.M. Watkins, and J.M. Olefsky GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects Cell 142 5 2010 687 698
43. V.J. Haupt, and M. Schroeder Old friends in new guise: repositioning of known drugs with structural bioinformatics Brief. Bioinform. 12 4 2011 312 326
44. M. Maggiolini, M.F. Santolla, S. Avino, F. Aiello, C. Rosano, A. Garofalo, and F. Grande Identification of two benzopyrroloxazines acting as selective GPER antagonists in breast cancer cells and cancer-associated fibroblasts Future Med. Chem. 7 4 2015 437 448
45. R. Lappano, C. Rosano, P. De Marco, E.M. De Francesco, V. Pezzi, and M. Maggiolini Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells Mol. Cell. Endocrinol. 320 1-2 2010 162 170
46. R. Lappano, C. Rosano, M.F. Santolla, M. Pupo, E.M. De Francesco, P. De Marco, M. Ponassi, A. Spallarossa, A. Ranise, and M. Maggiolini Two novel GPER agonists induce gene expression changes and growth effects in cancer cells Curr. Cancer Drug Targets 12 5 2012 531 542
47. C. Rosano, R. Lappano, M.F. Santolla, M. Ponassi, A. Donadini, and M. Maggiolini Recent advances in the rationale design of GPER ligands Curr. Med. Chem. 19 36 2012 6199 6206
48. M. Bello, M. Martinez-Archundia, and J. Correa-Basurto Automated docking for novel drug discovery Expert Opin. Drug Discov. 8 7 2013 821 834
49. J.D. Durrant, and J.A. McCammon Molecular dynamics simulations and drug discovery BMC Biol. 9 2011 71
50. H. Alonso, A.A. Bliznyuk, and J.E. Gready Combining docking and molecular dynamic simulations in drug design Med. Res. Rev. 26 5 2006 531 568
51. R. Lappano, C. Rosano, A. Pisano, M.F. Santolla, E.M. De Francesco, P. De Marco, V. Dolce, M. Ponassi, L. Felli, G. Cafeo, F.H. Kohnke, S. Abonante, and M. Maggiolini A calixpyrrole derivative acts as a GPER antagonist: mechanisms and models Dis. Models Mech. 2015 10.1242/dmm.021071 In Press
52. Y. Takada, C. Kato, S. Kondo, R. Korenaga, and J. Ando Cloning of cDNAs encoding G protein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress Biochem. Biophys. Res. Commun. 240 3 1997 737 741
53. M.F. Santolla, E.M. De Francesco, R. Lappano, C. Rosano, S. Abonante, and M. Maggiolini Niacin activates the G protein estrogen receptor (GPER)-mediated signalling Cell. Signal. 26 7 2014 1466 1475
54. S. Chakrabarti, and S.T. Davidge G-protein coupled receptor 30 (GPR30): a novel regulator of endothelial inflammation PLoS One 7 12 2012 e52357
55. E.M. De Francesco, R. Lappano, M.F. Santolla, S. Marsico, A. Caruso, and M. Maggiolini HIF-1alpha/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs) Breast Cancer Res. 15 4 2013 R64
56. B.S. Kong, Y.H. Cho, and E.J. Lee G protein-coupled estrogen receptor-1 is involved in the protective effect of protocatechuic aldehyde against endothelial dysfunction PLoS One 9 11 2014 e113242
57. C.M. Revankar, D.F. Cimino, L.A. Sklar, J.B. Arterburn, and E.R. Prossnitz A transmembrane intracellular estrogen receptor mediates rapid cell signaling Science 307 5715 2005 1625 1630
58. C. Sanden, S. Broselid, L. Cornmark, K. Andersson, J. Daszkiewicz-Nilsson, U.E. Martensson, B. Olde, and L.M. Leeb-Lundberg G protein-coupled estrogen receptor 1/G protein-coupled receptor 30 localizes in the plasma membrane and traffics intracellularly on cytokeratin intermediate filaments Mol. Pharmacol. 79 3 2011 400 410
59. E. Filardo, J. Quinn, Y. Pang, C. Graeber, S. Shaw, J. Dong, and P. Thomas Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane Endocrinology 148 7 2007 3236 3245
60. A. Madeo, and M. Maggiolini Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts Cancer Res. 70 14 2010 6036 6046
61. M. Pupo, A. Vivacqua, I. Perrotta, A. Pisano, S. Aquila, S. Abonante, A. Gasperi-Campani, V. Pezzi, and M. Maggiolini The nuclear localization signal is required for nuclear GPER translocation and function in breast cancer-associated fibroblasts (CAFs) Mol. Cell. Endocrinol. 376 1-2 2013 23 32
62. B.O. Nilsson, B. Olde, and L.M. Leeb-Lundberg G protein-coupled oestrogen receptor 1 (GPER1)/GPR30: a new player in cardiovascular and metabolic oestrogenic signalling Br. J. Pharmacol. 163 6 2011 1131 1139